anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic respiratory diseases (CRDs) require holistic management which considers patients' preferences, appropriate pharmacotherapy, pulmonary rehabilitation, and integrated care. We aimed to understand the perceptions of people with CRDs about their condition and pulmonary rehabilitation in Bangladesh.
METHODS: We conducted semi-structured interviews with a maximum variation sample of people with CRDs who had participated in a feasibility study of pulmonary rehabilitation in 2021/2022. A multidisciplinary team transcribed the interviews verbatim and analysed them in Bengali using a grounded theory approach.
RESULTS: We interviewed 15 participants with chronic obstructive pulmonary disease, asthma, or post-tuberculosis. The analysis revealed three themes. The first encompassed understanding CRDs: Patients characterised their condition by the symptoms (e.g. 'Hapani' meaning 'breathlessness') rather than describing a disease entity. Some believed occupation, previous infection, or family history to be a cause. The second theme included perceptions of pulmonary rehabilitation: Exercise was counterintuitive, as it exacerbated the breathlessness symptom that defined their disease. Views varied, though many acknowledged the benefits after a few sessions. Even with home-based programmes, participants described practical barriers to finding time for the sessions and adopted strategies to overcome the challenges. The third theme focused on implementation: Participants highlighted the need for raising awareness of CRDs and the potential of pulmonary rehabilitation in the community, adapting to the local context, and establishing an accessible resourced service.
CONCLUSIONS: Understanding how patients and their communities perceive their condition and the barriers (both conceptual and logistical) to acceptance is the first step to embedding this highly effective intervention into routine health care services in Bangladesh with potential benefits for the increasing number of people living with CRDs in low- and middle-income countries.
The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
Klebsiella pneumoniae is a common pathogen of nosocomial infection, which can cause pneumonia, urinary tract infection, cystitis, and bloodstream infections (BSIs). Here, we genetically characterize a novel carbapenem-resistant K. pneumoniae (CRKP) strain recovered from the blood of a 44-year-old male patient with severe acute necrotizing pancreatitis and septic shock in China. The strain is a ST45 K. pneumoniae with a novel serotype of K43, named 18SHX166. The susceptibility testing results showed that 18SHX166 was resistant to cephalosporin and carbapenems but still susceptible to ceftazidime-avibactam, quinolones, colistin, and amikacin. Genomic sequencing revealed that 18SHX166 contains three plasmids, namely pSHX166-Hv, pSHX166-KPC, and pSHX166-3. pSHX166-Hv harbored the iucABCD operon, encoding the siderophore of aerobactin. pSHX166-KPC harbored blaKPC-2 gene and possessed complete conjugative regions. The conjugation experiment verified pSHX166-KPC as a self-transmissible plasmid mediating the dissemination of antibiotic resistance, with a conjugation rate of 2.21 × 10-5. Additionally, the growth curve showed that 18SHX166 demonstrates a higher growth rate than the control strains. The characteristics of 18SHX166 indicate a potential high risk of clinical transmission.IMPORTANCEST45-K43 carbapenem-resistant Klebsiella pneumoniae isolate, 18SHX166, carries a carbapenem resistance plasmid and virulence plasmid. It has the characteristics of multidrug resistance, high transmissibility, and a fast growth rate, which could pose a threat to the control of antimicrobial resistance and clinical transmission, causing a severe challenge to public health.
This revised application is a clinical trial designed to evaluate crestal bone level changes when implants are placed into extraction sites and immediately provisionalized. Extraction of maxillary incisor teeth is a common procedure as documented in our school clinics. Traditional treatment when a tooth is extracted includes a period of healing followed by placement of an implant. Our preliminary data indicates that the delayed approach results in labial bone loss with resultant horizontal deficiency in over 50% of cases, requiring hard and soft tissue grafting to achieve a functional result. Additional preliminary data indicates that grafting the extraction site and/or immediate implant placement and provisionalization results in a functional restoration, without the need for additional adjunctive grafting procedures. It is unclear how the crestal bone levels change during healing of the extraction site prior to implant placement, in contrast to immediate implant placement, with immediate provisionalization with a crown. We hypothesize that there will be differences in the crestal bone levels (primary endpoint), and differences in soft tissue levels and indices (secondary endpoints) between implants immediately temporized, placed either delayed or immediately after tooth extraction, with more bone loss in the immediate placement group (experimental) compared to the delayed placement group (control). The long-term goal is to determine if the crestal bone remodeling after tooth extraction or the apical position of the implant determines the final level of the crestal bone. Two groups of 45 patients will be evaluated. All subjects will have a single rooted maxillary tooth extracted. One group will have the socket grafted with mineralized bone and allowed four months prior to implant placement. The crestal bone in this group will have remodeled during the four months of healing prior to implant placement. The second group will have the implant placed immediately after tooth extraction, thus the crestal bone will remodel in the presence of the implant and the immediately placed temporary restoration, as a one-stage procedure. For both groups, the implants will be immediately temporized with a crown after implant placement. Standardized hard and soft tissue data will be collected pre-extraction as baseline, and then prospectively for at least two years in this trial, to compare the methods and contrast the effectiveness of the proposed immediate restoration therapy.
DSM-V criteria for Alcohol use Disorder. At least 8 heavy drinking episodes in the past month. Abstinent for at least 2 weeks and no more than 4 weeks. Less than 20 lifetime cigarettes or equivalent. No history of addiction to any other substances or gambling.
The scope of the study, including patients over 18 years of age who applied to the Neurology outpatient clinic of Sani Konukoğlu Application and Research Hospital and presented with cervicogenic headache by a specialist. The sometimes headache frequency variable in the reference result was 5% Power analysis calculated 9 patients per group. It was decided to recruit 15 patients for the group. Inclusion criteria: CH was diagnosed, aged 18-65, had not received medical (except analgesic) treatment or physiotherapy for CH in the previous few months. Exclusion criteria: Individuals who have undergone CH surgery, history of serious heart or surgery, history of ongoing malignancy, diagnosed with epilepsy. Individuals for whom the Voluntary Consent form will be obtained will be randomly divided into groups using the minimalization method given age, gender and duration of illness.Patients will be asked not to use analgesics as much as possible during the treatment period. In the case of analgesic use, the amount and frequency will be recorded. The change in the frequency of analgesic use will also be used to evaluate the effectiveness of the applications.
The invention relates to a height increasing shoe pad. The height increasing shoe pad has two characteristics of being attractive and having medical effects. The height increasing shoe pad is based on sachets and embroidery of Qingyang, Gansu, highlights folk embroidery skills, and absorbs folk Chinese herbal medicine secret recipes, fragrance formulas and the like. The height increasing shoe pad has the medical effects of promoting blood circulation and removing stasis, being fragrant, and clearing damp and relieving itching, has natural fragrance, makes full use of heat and sweat generated by human bodies, and promotes mixed components of Chinese herbal medicine and fragrance to volatilize towards the direction of the human bodies. Pure cotton cloth contacting the human bodies is good in permeability and favorable for body surfaces to absorb and use the Chinese medicine components. More than 30 acupoint areas and reflection areas exist in a sole densely, medicine is supplied to the acupoints through blood capillaries of skin and moves to five viscera and six entrails through meridians so as to achieve external treatment for internal diseases and lower treatment for upper diseases, dredge meridians of human bodies, activate blood and restore mental clarity, condition organism, improve human body functions, promote blood circulation, adjust a nerve system, and improve immune competence. The height increasing shoe pad is extension of functions and technology of Qingyang sachet products.
Techniques described herein relate generally to capturing subject data in dynamic environments using mobile cameras. In various embodiments, first image data generated by a mobile device (102) equipped with a camera (104) may be obtained (302) and analyzed (304). Based on the analysis, at least one configuration may be selected (306) for the camera. The mobile device may be provided (312) with data indicative of the selected at least one configuration. Second image data generated by the mobile device after provision of the data indicative of the selected at least one configuration may be provided (312). The second image data may capture a subject. The second image data may be processed (316) to extract at least one vital sign of the subject.
Treatment for hypertension includes lifestyle changes and medications. Examples of some antihypertensive medications include diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and vasodilators. Mounting research suggests that certain antihypertensive medications, such as thiazide diuretics, are associated with metabolic disturbances that result in increased glucose intolerance, while other antihypertensive medications, such as ACE inhibitors and ARBs, appear to improve insulin sensitivity and glucose metabolism. The influence of these medications may be especially critical in people with metabolic syndrome, who are already at risk of developing glucose intolerance and diabetes. The purpose of this study is to gain an understanding of how people with metabolic syndrome respond to antihypertensive medications that alter the body's ability to break down sugar. The long-term goal of the study is to determine the best antihypertensive medications for people who have both metabolic syndrome and hypertension so as to prevent or delay the onset of diabetes in this population.

Participation in this study will last 18 weeks and involve four study visits. Participants will be randomly assigned to initially receive 6 weeks of treatment with either hydrochlorothiazide (HCTZ), which is a thiazide diuretic, or trandolapril, which is an ACE inhibitor. Both medications are FDA-approved for treating hypertension. After 6 weeks of treatment, if participants' blood pressure levels are not too low, they will add the second medication so that they are taking both HCTZ and trandolapril for the next 6 weeks, until Week 12. At Week 12, again if participants' blood pressure levels are not too low, they will then take only the second medication for the last 6 weeks. The four study visits will occur at baseline and after each of the three 6-week treatment periods (Weeks 6, 12, and 18). All study visits will include blood pressure and pulse measurements, urine and blood sampling, oral glucose tolerance testing, and questions about diet and exercise habits. The first and last study visits will also include a physical examination and a medical history review. Some of the blood collected during the first study visit will be used for genetic testing. There will be no follow-up visits.
<P>PROBLEM TO BE SOLVED: To obtain a kit and a composition for treating dental caries of period C1 or period C2 and root caries.  <P>SOLUTION: The kit and the composition for dental caries treatment comprises (1) a hydroxyapatite particle-containing composition, and (2) a phosphorylated saccharide of calcium. The dental caries is dental caries of period C1 and period C2 and root caries. The phosphorylated saccharide of calcium comprises a saccharide part and a phosphate group calcium salt. The saccharide part is a glucan having a polymerization degree of 2-8. The number of the phosphate groups is 1-2.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
FIELD: medicine, endocrinology. SUBSTANCE: method involves administration of ozonized 0.9% sodium chloride solution at ozone concentration 3.5-5.0 mg/l by intravenous route by drops for 30 min at amount 400 ml/day for 5 days to patients after operation associated with thyroid sicknesses at the background of autoimmune thyroiditis at postoperative period and to patients after conservative treatment. Treatment course involves 5 procedures. Method results to immunocorrection, improves results of surgery operations, enhances effectiveness of the complex treatment of nonoperated patients. EFFECT: improved and enhanced effectiveness of treatment, simplified simple and safety method, absence of complications. 2 ex
PURPOSE:To obtain a polyhydric alcohol in oil type emulsion composition excellent in viscosity, stability and use properties even in a system having a polar oil component compounded therein, by using clay mineral modified with an org. substance, which is obtained by treating water swellable clay mineral with a specific surfactant, as an emulsifier. CONSTITUTION:60-140mg equivalent of a quaternary ammonium salt type cationic surfactant represented by formula (wherein R1 is a 10-22 alkyl group or a benzyl group, R2 is a methyl group or a 10-22C alkyl group, R3 and R4 are an 1-3C alkyl group or a hydroxyalkyl group and X is a halogen atom or a methylsulfate residue) and 5-200g of a nonionic surfactant with a HLB valve of 2-16 are added to 100g of water swellable clay mineral represented by formula I and the resulting mixture is dispersed in a low b.p. solvent under stirring and the solvent is subsequently removed to obtain an organically modified clay mineral which is, in turn, used in a reduced compounding amount of 0.25-5wt% to obtain a polyhydric alcohol in oil type emulsion composition excellent in temp. stability. As an oil component to be used, all of general oil components can be used in a wide range from polar oil to non-polar oil and this emulsion composition can be utilizing in wide fields of medicine, cosmetics, paint, etc.
PROBLEM TO BE SOLVED: To obtain inorganic compounds capable of developing mineral function in vivo by metabolism of Bacillus natto and Bacillus subtilis and contributing for health maintenance by culturing Bacillus natto and Bacillus subtilis in a liquid culture medium on which Bacillus natto and Bacillus subtilis are parasitic or in which these bacteria are inoculated. SOLUTION: An inorganic crystal is obtained by metabolizing Bacillus natto and Bacillus subtilis (hereinafter referred to as Bacillus subtilis or the like) in a liquid culture medium in which Bacillus subtilis or the like are parasitic or in which Bacillus subtilis or the like are inoculated. Furthermore, the crystal has the following physicochemical properties. Elemental analysis: N 5.05%, C 0.47%, H 5.85%. Elements detected by emission spectrochemical analysis: Mg and P contents: larger amounts; Ca, Mn and Fe contents: small amounts; Si content: smaller amount; Na content: a trace amount. Color, transparent in water and translucent or white in air. Solubility, insoluble in water, an aqueous alkali solution, alcohols, etc., and readily soluble in an aqueous acid solution.  An inorganic acid salt (BYC), by-product (BBP), a mixture thereof (BAHC) and a substance whose ion form is similar to that of BTC and BAHC are obtained by dissolving the inorganic substances into hydrochloric acid, pouring these substances into water, treating the liquid with activated carbon, filtering the liquid and drying the filtrate.
Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
Eighteen million people in the United States are currently suffering from Major Depressive Disorder, which is characterized by episodes of low mood, poor self attitude and poor vitality. Of those suffering from Major Depressive Disorder (MDD), only one third completely improve, but even among these cases, there is a waiting period of several weeks or more during which antidepressants take effect. Our inability to adequately treat MDD is evident in its being ranked number one in Disability Adjusted Life Years (DALY) among persons aged 15-44. Given this profound burden, improving our understanding of the molecular basis of MDD is of utmost importance in the development of novel antidepressant medications.

Serotoninergic neurotransmission is implicated in MDD, as demonstrated by the relative success of selective serotonin reuptake inhibitors (SSRIs). SSRIs block the reuptake of serotonin through the serotonin transporter, which then increases serotonin at the synaptic cleft. Serotonin then binds to 5-HT(1A) receptors, which are G-protein coupled receptors that are present both presynaptically and postsynaptically. Presynaptically, these receptors act as autoinhibitory receptors, triggering decreased firing rates and decreased serotonin release. This autoinhibitory mechanism is believed to be the reason why patients experience a delay in symptomatic improvement after initiation of SSRIs. Serotonin binding to postsynaptic receptors mediates symptomatic improvement of depression. Multiple positron emission tomography (PET) studies on 5-HT(1A) have been published. However, none of these studies use 5-HT(1A) agonists, which are specific for the high affinity, G-protein coupled and active state of the 5-HT(1A) receptor. We would therefore like to establish the use of the 5-HT(1A) radiolabelled agonist, \[(11)C\]CUMI, here at NIH.

The purpose of this study is to perform whole body PET studies in healthy volunteers in order to estimate radiation absorbed doses for \[(11)C\]CUMI. Future experiments will include studies on Major Depressive Disorder.
A refreshing and cool patch and a preparation method thereof. The invention discloses the refreshing and cool patch which includes a refreshing and cool patch body. The refreshing and cool patch body is composed of a back lining layer, a high-molecular gel layer and an anti-binding layer. The anti-binding layer is arranged at an upper layer of the high-molecular gel layer. The back lining layer is arranged at a lower layer of the high-molecular gel layer. The high-molecular gel layer includes following components, by weight: 30-32% of a high-molecular gel material, 1-2% of medicinal alcohol being 75% in mass concentration, 1-2% of mint essential oil, 1-1.5% of rosemary essential oil and 1.1-1.2% of chemical additives, wherein the components are added with pure water to 100%. The invention also discloses the preparation method of the refreshing and cool patch. The mint essential oil has a high-efficient temperature-reducing effect and has a mint fragrance which is cool and refreshing and can excite spirit. The rosemary essential oil has a strong shrinkage effect, can tightening loosened skin, and can reduce hyperemia and swelling. The refreshing and cool patch has effects of exciting spirit and refreshing head, alleviating fatigue and improving attention and is long in refreshing durability.
The present invention relates to a medicine for treating ulcer, which is prepared from 10 to 40 of pilose asiabell root, 5 to 20 of largehead atractylodes rhizome, 5 to 30 of poria from Yunnan of China, 5 to 25 of bupleurum root, 5 to 30 of finger citron, 2 to 20 of prepared liauorice root, 10 to 50 of cuttlebone, 5 to 35 of calcined concha arcae, 5 to 35 of tuber of hyacinth bletilla, 5 to 30 of thunberg fritillary bulb, 5 to 30 of notoginseng, 5 to 35 of rhizoma corydalis, 5 to 35 of white peony root and 3 to 20 of diverse wormwood herb. The medicine can regulate, treat, repair and protect the stomach and duodenum in a systematic and comprehensive mode in multiple angles and multiple layers, such as benefiting vital energy, activating blood circulation, inhibiting acid, repairing the membrane, protecting the membrane, sterilizing bacteria, etc. Thus, the medicine has the characteristics of quick effect, short course of treatment, high therapeutic effect, etc. In addition, the medicine has a better therapeutic effect on common digestive system diseases, such as chronic gastritis, etc. The treatment cost of the medicine is low, and can be accepted by common patients. Through application in local municipal hospitals and outpatient departments for more than three years, the effective rate of the medicine reaches 100%, and the cure rate is as high as 96%.
Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
After 2 cycles of anlotinib treatment, we evaluate the therapeutic effect of tumor treatment: If it achieve downgrading and is operable, surgical treatment will be performed; if it is still inoperable and could accept radiotherapy, radiotherapy and chemotherapy will be combined with oral chemotherapy of anlotinib until the end of radiotherapy. Efficiency and side effects will be evaluated within 3 months after therapy. Finally, the survival is in follow-up.